| Literature DB >> 27721914 |
Md Asiful Islam1, Fahmida Alam1, Md Solayman2, Md Ibrahim Khalil3, Mohammad Amjad Kamal4, Siew Hua Gan1.
Abstract
Cumulatively, degenerative disease is one of the most fatal groups of diseases, and it contributes to the mortality and poor quality of life in the world while increasing the economic burden of the sufferers. Oxidative stress and inflammation are the major pathogenic causes of degenerative diseases such as rheumatoid arthritis (RA), diabetes mellitus (DM), and cardiovascular disease (CVD). Although a number of synthetic medications are used to treat these diseases, none of the current regimens are completely safe. Phytochemicals (polyphenols, carotenoids, anthocyanins, alkaloids, glycosides, saponins, and terpenes) from natural products such as dietary fruits, vegetables, and spices are potential sources of alternative medications to attenuate the oxidative stress and inflammation associated with degenerative diseases. Based on in vitro, in vivo, and clinical trials, some of these active compounds have shown good promise for development into novel agents for treating RA, DM, and CVD by targeting oxidative stress and inflammation. In this review, phytochemicals from natural products with the potential of ameliorating degenerative disease involving the bone, metabolism, and the heart are described.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27721914 PMCID: PMC5046019 DOI: 10.1155/2016/5137431
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1Inflammation and oxidative stress-mediated pathogenesis of (a) cardiovascular disease, (b) diabetes mellitus, and (c) rheumatoid arthritis.
Mechanism of action and side effects of some synthetic regimens used in the treatment of CVD, DM, and RA.
| Number | Drugs | Mechanism | Side effects | Structure |
|---|---|---|---|---|
|
| ||||
|
| ||||
| 1 | Aspirin | (i) Inhibiting the production of TXA2 by inactivation of COX-1 and COX-2 enzymes | (i) Stomach bleeding |
|
|
| ||||
| 2 | Quinapril | (i) Inhibiting ACE which catalyzes the formation of angiotensin II (a strong vasoconstrictor) | (i) Dizziness |
|
|
| ||||
| 3 | Digoxin | (i) Inhibiting the Na-K-ATPase membrane pump resulting in an increase in intracellular sodium | (i) Dizziness |
|
|
| ||||
| 4 | Amlodipine | (i) Decreasing arterial smooth muscle contractility and vasoconstriction by inhibiting the influx of calcium ions through calcium channels | (i) Dizziness |
|
|
| ||||
| 5 | Isosorbide dinitrate | (i) It is converted into NO which activates the enzyme guanylate cyclase that stimulates the synthesis of cGMP which then activates a series of protein kinase-dependent phosphorylations in the smooth muscle cells eventually resulting in vasodilation | (i) Headache |
|
|
| ||||
|
| ||||
|
| ||||
| 1 | Metformin (Glucophage®) | (i) Activating AMPK to inhibit hepatic glucose production | (i) Lactic acidosis |
|
|
| ||||
| 2 | Pioglitazone | (i) Activating PPAR | (i) Weight gain |
|
|
| ||||
| 3 | Glibenclamide | (i) Binding and inhibiting the ATP-sensitive potassium channels SUR1 receptor on the pancreatic cell surface, which causes membrane depolarization and opens the calcium channels for insulin exocytosis | (i) Nausea |
|
|
| ||||
| 4 | Acarbose | (i) Reversibly binding to pancreatic | (i) Diarrhea |
|
|
| ||||
| 5 | Human insulin | (i) Binding to the IR and stimulating the downstream signaling molecules which regulates the GLU4 and PKC activity | (i) Pain |
|
|
| ||||
|
| ||||
|
| ||||
| 1 | Methotrexate | (i) Inhibiting dihydrofolate reductase which is involved in purine metabolism | (i) Nausea |
|
|
| ||||
| 2 | Hydroxychloroquine | (i) Inhibiting stimulation of the TLR-9 | (i) Nausea |
|
|
| ||||
| 3 | Sulfasalazine (Azulfidine®) | (i) Inhibiting NF- | (i) Stomach upset |
|
|
| ||||
| 4 | Leflunomide | (i) Inhibiting mitochondrial enzyme dihydroorotate dehydrogenase and thus inhibiting the reproduction of rapidly dividing cells, especially autoimmune lymphocytes | (i) Diarrhea |
|
|
| ||||
| 5 | Certolizumab | (i) Binding and neutralizing the activity of TNF | (i) Fever |
|
AMPK: AMP-activated protein kinase; GLUT4: glucose transporter 4; SUR1: sulfonylurea receptor 1; IR: insulin receptor, PKC: protein kinase C; PPARγ: peroxisome proliferator-activated receptor gamma; ATP: adenosine triphosphate; TXA2: thromboxane A2; COX: cyclooxygenase: AST: aspartate aminotransferase; ALT: alanine aminotransferase; ACE: angiotensin converting enzyme; NO: nitric oxide; cGMP: cyclic guanosine 3′,5′-monophosphate.
Evidence of clinical trials with natural products attenuating oxidative stress and inflammation in patients with CVD, DM, and RA.
| Number | Type of study | Number of participants | Age (years) | Intervention | Comparison/control | Period of intervention | Outcomes | Year [references] |
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
|
| ||||||||
| 1 | Randomized controlled crossover trial | 30 (F = 24, M = 6) | 47.3 ± 13.6 | Control, apple, spinach, and apple + spinach | Healthy control | 4 weeks | All treatments showed higher flow-mediated dilatation (FMD) ( | 2012 [ |
|
| ||||||||
| 2 | Double-blind randomized crossover trial | M = 30 | 52.6 ± 5.5 | Two lyophilized apples (40 g), polyphenol-rich and polyphenol-poor, providing, respectively, 1.43 g and 0.21 g polyphenols per day | Hypercholesterolemic | 6 weeks | FMD did not differ between the polyphenol-rich and the polyphenol-poor apples, neither did the other cardiovascular disease risk factors (plasma lipids, homocysteine, and antioxidant capacity) | 2010 [ |
|
| ||||||||
| 3 | Open prospective randomized crossover controlled feeding trial | 40 (F = 21, M = 19) | 28 ± 11 | Raw tomatoes/kg (7.0 g), 3.5 g of tomato sauce/kg, 3.5 g of tomato sauce with refined olive oil/kg, and 0.25 g of sugar solved in water/kg | Healthy control | 12 days | Tomato sauce enriched with refined olive oil can regulate lipid profile and soluble inflammatory biomarkers better than raw tomatoes or tomato sauces | 2016 [ |
|
| ||||||||
| 4 | Double-blind controlled randomized trial | F = 79 | 56 ± 4 | Genistein from soybeans (54 mg/day); estrogen/progestin therapy (1 mg/day); estrogen/progestin combined with norethisterone acetate (0.5 mg/day) | Healthy postmenopausal women | 1 year | Genistein therapy improved endothelium function similar to estrogen/progestin regimen | 2003 [ |
|
| ||||||||
| 5 | Double-blinded placebo-controlled crossover trial | 93 (F = 51, M = 42) | 25–65 | Quercetin/day from fruits and vegetable sources (150 mg) | Overweight/obese | 6 weeks | Reduced SBP and plasma oxidized LDL level with a high-CVD risk phenotype | 2009 [ |
|
| ||||||||
| 6 | Double-blinded randomized placebo-controlled crossover trial | M = 31 | 35–51 | Anthocyanins from fruits and vegetable sources (640 mg/day) | Prehypertensive | 4 weeks | HDL-C and blood glucose were significantly higher after anthocyanin versus placebo treatment ( | 2013 [ |
|
| ||||||||
| 7 | Randomized double-blind placebo-controlled clinical trial | 105 | 20–60 | One 350 mg whortleberry extract capsule every 8 hours | Hyperlipidemic | 2 months | Lowered total-C ( | 2014 [ |
|
| ||||||||
| 8 | Randomized double-blind placebo-controlled clinical trial | 50 | ≥18 | 45 ± 2 mg of anthocyanin from | Hyperlipidemic | 4 weeks | Significantly reduced total-C ( | 2014 [ |
|
| ||||||||
| 9 | Randomized controlled investigator blinded parallel-group trial, | 44 (F = 24, M = 20) | 56–73 | Dark chocolate (6.3 g/day) containing 30 mg of polyphenols | Stage-1 hypertensive | 18 weeks | Reduced mean (SD) SBP by 2.9 (1.6) mmHg ( | 2007 [ |
|
| ||||||||
| 10 | Randomized placebo-controlled single-blind crossover trial, | 45 (F = 35, M = 10) | 30–75 | In phase 1, solid dark chocolate bar (containing 22 g cocoa powder) or a cocoa-free placebo bar. In phase 2, sugar-free cocoa (containing 22 g cocoa powder), sugared cocoa (containing 22 g cocoa powder), or a placebo | Healthy control | 1 week | The acute ingestion of both solid dark chocolate and liquid cocoa improved endothelial function and lowered blood pressure in overweight adults | 2008 [ |
|
| ||||||||
|
| ||||||||
|
| ||||||||
| 11 | Open label randomized clinical trial | 60 | 35–55 | Standard metformin therapy with turmeric (2 g) supplements | Standard metformin treatment | 4 weeks | Turmeric administered group significantly ( | 2015 [ |
|
| ||||||||
| 12 | Randomized double-blind controlled clinical trial | 70 | 30–70 | Powdered rhizome of ginger (1600 mg) | Wheat flour placebo (1600 mg) | 12 weeks | Ginger significantly reduced the fasting plasma glucose, HbA1c, insulin, triglyceride, total cholesterol, CRP, and PGE2 | 2014 [ |
|
| ||||||||
| 13 | Randomized triple-blind controlled trial | M = 35 | 60 ± 11 | Capsule of 350 mg of RES enriched grape extract (GE) | 350 mg of capsules containing either maltodextrin (placebo) or RES lacking GE | 12 months | RES enriched GE downregulated the proinflammatory cytokines expression via involving the inflammation-related miRs in circulating immune cells | 2013 [ |
|
| ||||||||
| 14 | Randomized double-blind controlled trial | 36 (F = 23, M = 13) | 51.5 ± 10.0 | FDS beverage of 2 cups (50 g of FDS is equivalent to 500 g of fresh strawberries) | Placebo powder with strawberry flavor | 6 weeks | FDS significantly ( | 2013 [ |
|
| ||||||||
| 15 | Randomized double-blind controlled trial | 64 | 38–65 | Ginger supplementation | Placebo | 8 weeks | Ginger supplementation significantly reduced the TNF- | 2013 [ |
|
| ||||||||
| 16 | Randomized double-blind clinical trial | 81 | 18–60 | BSP at 10 g/day ( | Placebo | 4 weeks | BSP significantly decreased the MDA, OSI, and oxidized low density lipoprotein cholesterol and increased the TAC | 2011 [ |
|
| ||||||||
| 17 | Double-blinded randomized crossover trial | 32 (M = 16, F = 16) | 61.8 ± 6.4 | GSE (600 mg/day) | Placebo | 4 weeks | GSE significantly improved the inflammatory markers (mainly CRP), glycemia, and oxidative stress | 2009 [ |
|
| ||||||||
|
| ||||||||
|
| ||||||||
| 18 | Randomized single-blind pilot study | 45 (F = 38, M = 7) | 47.8 ± 8.6 | Curcumin (500 mg) and diclofenac sodium (50 mg) alone or in combination | Diclofenac sodium (anti-inflammatory drug) | 8 weeks | Curcumin alone proved to be the most effective ( | 2012 [ |
|
| ||||||||
| 19 | Randomized double-blind placebo-controlled crossover study | 20 (F = 19, M = 1) | 52.1 ± 10.3 | Quercetin (166 mg/capsule) + vitamin C (133 mg/capsule); | Placebo | 6 weeks | No significant difference was found among the proinflammatory cytokines; however quercetin tended to reduce VAS of RA | 2009 [ |
|
| ||||||||
| 20 | Randomized double-blind placebo-controlled study | 105 | 55–75 | Polyphenolic-rich olive extract | Placebo | 8 weeks | Significant ( | 2007 [ |
F: female; M: male; RA: rheumatoid arthritis; VAS: visual analogue scale; NR: not reported; CRP: C-reactive protein; RES: resveratrol; GE: grape extract; miRs: microRNAs; FDS: freeze-dried strawberry; MDA: malondialdehyde; GSE: grape seed extract; BSP: broccoli sprouts powder; OSI: oxidative stress index; TAC: total antioxidant capacity; PGE2: prostaglandin E2; HbA1c: glycosylated hemoglobin; CAD: coronary artery disease; LDL-C: low density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol; SBP: systolic blood pressure.